|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 414.60 DKK | -2.22% |
|
-5.55% | -33.58% |
| 18/07 | Fangzhou Inc. and Novo Nordisk Signs Collaboration Memorandum to Establish A New Ecosystem for Health Management | CI |
| 18/07 | NOVO NORDISK : UBS keeps its Buy rating | ZD |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Other Pharmaceuticals
| Capi. | Sales growth | Profitability (Composite) | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
| 29TCr | ||||||
| 69TCr | ||||||
| 39TCr | ||||||
| 33TCr | ||||||
| 26TCr | ||||||
| 22TCr |
- Stock Market
- Equities
- NOVO B Stock
- Charts Novo Nordisk A/S
- Sector Chart
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition